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A comprehensive review of Australia’s National Cervical Screening Program (NCSP), the Renewal, has been undertaken over the past few years.1 This 
review recommended a number of changes, including 
that human papillomavirus (HPV) testing replace con-
ventional cytology (ie, Pap tests) as the primary screening 
test, with 5-yearly screening commencing at age 25. The 
proposals have been endorsed by the Medical Services 
Advisory Committee (MSAC).2
The Renewal deliberations also considered the question 
of the recruitment of women who had never been 
screened or who were underscreened, a significant 
concern because it has been estimated that 80% of 
cervical cancers are diagnosed in these women.1 One 
proposed solution is to offer a separate self-sampling 
HPV testing pathway, as studies, both in Australia3 and 
internationally,4 have shown self-sampling to increase 
recruitment and to be advantageous in underscreened 
women. The Renewal proposal is that the self-sampling 
option be organised by a clinician who also offers routine 
screening. It would be offered to women who have not 
been screened during the previous 6 years, or who have 
never been screened and have declined to participate in 
the mainstream screening pathway. The sample would 
be taken by the patient, possibly in the clinic, and sent 
to the laboratory for testing. If the sample is positive 
for HPV, the patient would be asked to return to give a 
cytology sample.
This edition of the MJA includes the report on a study 
by Smith and colleagues that compared the benefits 
of self-sampling HPV testing with the mainstream 
screening program.5 One consideration for the NCSP 
was that offering two different screening options might 
cause confusion. Some women who normally undergo 
screening may even prefer the self-sampling option. Smith 
and colleagues, using a dynamic modelling approach, 
clearly established that self-sampling is associated with 
a lower risk of a cervical cancer diagnosis than not being 
screened. However, it also found that HPV testing as part 
of the recommended mainstream screening program 
has clear advantages over the self-sampling pathway, 
and that women should avail themselves of this option.
The importance of education and communication is well 
illustrated by the self-sampling question. Self-sampling 
has already received quite significant publicity in 
mainstream media; however, there appear to be many 
misconceptions. Many of the reports, for example, imply 
that self-sampling was the only significant change 
recommended and that it is significantly beneficial. 
Headlines such as “Australian women will be able 
to do their own Pap smear”6 and “You could soon be 
doing your own Pap smear”7 have appeared online. Such 
comments are confusing and misleading for both the 
general public and the medical profession. The study by 
Smith and colleagues is therefore important, as it clearly 
establishes that there are two different testing pathways 
to be preferred under different circumstances.
This difference in the two pathways also highlights 
how the test result can be affected by the nature of 
the sample and the type of HPV testing. At the last 
count, more than 500 different types of HPV testing are 
available worldwide. The technology of HPV testing is 
complex and variable, and, until the commencement of 
the new program, will have predominantly been used 
as a diagnostic rather than a screening test. Validated 
assays that assure high quality screening must be used. 
A recent article suggested that only HPV tests that have 
been subjected to large randomised trials with a long 
cohort follow-up be used.8 The Netherlands has recently 
introduced HPV self-sampling as the primary screening 
test, but, unlike Australia, has designated one specific 
type of high risk HPV assay for use.9 
The Australian Renewal recommends that any type of 
HPV test can be used, but that the test must meet certain 
quality criteria. The study by Smith and colleagues points 
out that, although self-sampling has been shown to be 
beneficial, it is dependent on the nature of the HPV assay. 
Specific quality standards for self-sampling HPV testing 
will need to be set. The National Pathology Accreditation 
Advisory Council (NPAAC) is in the process of setting 
quality parameters for HPV testing and will consider 
the criteria for the two pathways.10 Laboratories will 
be left to choose which type of HPV test they perform, 
but the testing will have to fulfil the quality standards 
mandated by NPAAC.
The proposed changes to cervical screening are major 
and will need accurate and concise information to be 
distributed to both sample takers and women. The 
message from Smith and her colleagues is quite clear: 
self-sampling offers an alternative pathway for women 
who will not participate in routine screening, but it is 
significantly less beneficial than mainstream cervical 
screening. For both screening pathways, the quality of the 
HPV assay will be crucial to the success of the program 
and the safety of women.
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